- Report
- February 2024
- 250 Pages
Global
From €4802EUR$5,000USD£4,100GBP
- Report
- January 2024
- 200 Pages
Global
From €4802EUR$5,000USD£4,100GBP
- Report
- January 2022
- 191 Pages
Global
From €4082EUR$4,250USD£3,485GBP
- Drug Pipelines
- July 2022
- 100 Pages
Global
From €2641EUR$2,750USD£2,255GBP
- Report
- February 2021
- 30 Pages
Global
From €3121EUR$3,250USD£2,665GBP
- Report
- August 2022
- 111 Pages
Global
From €4106EUR$4,275USD£3,505GBP
€4562EUR$4,750USD£3,895GBP
- Report
- August 2018
- 20 Pages
Global
From €9604EUR$10,000USD£8,199GBP
Breakthrough Therapies are a type of pharmaceutical drug that has been developed to treat serious or life-threatening diseases. These drugs are typically developed using innovative technologies and have the potential to provide substantial improvements in the safety and effectiveness of treatments. Breakthrough Therapies are typically developed to treat conditions that have not responded to existing treatments, or to provide treatments for conditions that have no existing treatments.
Breakthrough Therapies are typically developed through a rigorous process of clinical trials and regulatory approval. This process is designed to ensure that the drug is safe and effective for its intended use. Once approved, Breakthrough Therapies are typically made available to patients through prescription.
Some companies in the Breakthrough Therapies market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more